Bio­gen climbs high­er on Spin­raza sales; inks deal for two new neu­ro­mus­cu­lar drugs

Bio­gen is climb­ing on the Nas­daq Tues­day morn­ing fol­low­ing news that it’s ac­quired two ear­ly-stage drugs for neu­ro­mus­cu­lar dis­or­ders, adding to the com­pa­ny’s pipeline of po­ten­tial pay­outs.

The an­nounce­ment came wrapped in the biotech gi­ant’s sec­ond quar­ter fi­nan­cial state­ments, which al­so not­ed Bio­gen’s Spin­raza sales had climbed to $423 mil­lion in Q2, more than dou­ble the sec­ond quar­ter fig­ure in the same pe­ri­od last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER